Gene · 29968
Papers1,996
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,996
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Post-translational regulation of human D-3-phosphoglycerate dehydrogenase in Alzheimer's disease. | Protein Sci | 2026 | 41711160 | PubTator, text mining | PubMed |
| Metabolic remodeling and immune evasion in glioblastoma: a focus on serine and lipid networks. | Front Oncol | 2026 | 41710656 | PubTator, text mining | PubMed |
| ΔNp63α drives serine synthesis to promote carboplatin resistance in NSCLC. | Cell Death Dis | 2026 | 41702885 | PubTator, text mining | PubMed |
| Mothers against decapentaplegic homolog 4 as a proteomic hub in vascular remodeling and residual cardiovascular risk. | World J Cardiol | 2026 | 41694032 | PubTator, text mining | PubMed |
| USP30 senses serine/glycine levels to regulate serine biosynthesis and colorectal tumorigenesis by deubiquitinating FTO. | Cell Death Differ | 2026 | 41652187 | PubTator, text mining | PubMed |
| Transcription Factor 21 Inhibits Prostate Cancer Progression via Transcriptional Repression of PSAT1. | Tohoku J Exp Med | 2026 | 41638670 | PubTator, text mining | PubMed |
| XPR1 downregulation inhibits hepatocellular carcinoma progression by suppressing serine metabolism. | Redox Biol | 2026 | 41592436 | PubTator, text mining | PubMed |
| Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications. | Signal Transduct Target Ther | 2026 | 41582215 | PubTator, text mining | PubMed |
| An improved united-atom potential for molecular dynamics simulation of saturated properties of n-alkanes. | J Chem Phys | 2026 | 41568806 | PubTator, text mining | PubMed |
| Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance. | Adv Sci (Weinh) | 2026 | 41560687 | PubTator, text mining | PubMed |
| Construction of biomimetic gradient-structured cartilage organoids and mechanistic study of their application for cartilage rejuvenation. | Bioact Mater | 2026 | 41551764 | PubTator, text mining | PubMed |
| Targeting FOXM1/PSAT1 axis by Brusatol inhibits lung cancer malignant progression. | Pathol Res Pract | 2026 | 41548464 | PubTator, text mining | PubMed |
| Vapor pressure measurements on Δ9-tetrahydrocannabinol, cannabidiol, and cannabinol to inform cannabis breathalyzer development. | J Breath Res | 2026 | 41529405 | PubTator, text mining | PubMed |
| Andrographolide blocked the progression of endometriosis by promoting ferroptosis via inhibiting anabolism of serine. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 41408483 | PubTator, text mining | PubMed |
| ONECUT1 activates PSAT1 to facilitate PD-L1 expression and mediate immune evasion of lung squamous cell carcinoma. | Tissue Cell | 2026 | 40907151 | PubTator, text mining | PubMed |
| PSAT1 inhibits mTORC1 activation by preventing Rag heterodimer formation in lung adenocarcinoma. | Autophagy | 2026 | 40702660 | PubTator, text mining | PubMed |
| A novel phage satellite class induces prophage excision in Mycolicibacterium aichiense. | bioRxiv | 2025 | 41573863 | PubTator, text mining | PubMed |
| A PSAT1 buff of YBX1 transcriptionally sustains HLA-E-mediated evasion of NK immunity. | Proc Natl Acad Sci U S A | 2025 | 41428871 | PubTator, text mining | PubMed |
| Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer. | J Genet Eng Biotechnol | 2025 | 41386839 | PubTator, text mining | PubMed |
| Association between SQSTM1 dysregulation and risk in alopecia areata: a Mendelian randomization study. | Front Immunol | 2025 | 41376639 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/29968/papers?page=3